Immunology of THymectomy And childhood CArdiac transplant (ITHACA): protocol for a UK-wide prospective observational cohort study to identify immunological risk factors of post-transplant lymphoproliferative disease (PTLD) in thymectomised children

• Published in: BMJ open Vol. 13; no. 10; p. e079582
• Main Authors: Offor, Ugonna T, Hollis, Paolo, Ognjanovic, Milos, Parry, Gareth, Khushnood, Abbas, Long, Heather M, Gennery, Andrew R, Bacon, Chris M, Simmonds, Jacob, Reinhardt, Zdenka, Bomken, Simon
• Format: Journal Article
• Language: English
• Published: London British Medical Journal Publishing Group 21.10.2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Protocol
• Subjects: Cohort analysis; Cytomegalovirus; Epstein-Barr virus; Heart transplants; Hospitals; Iatrogenesis; IMMUNOLOGY; Infections; Informed consent; Kidney transplants; Laboratories; Lymphocytes; Lymphoma; Observational studies; Observational Study; Paediatric oncology; Paediatric transplant surgery; Paediatrics; Patients; Pediatrics; Risk Factors; Viral infections; United Kingdom > UK
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2023-079582

IntroductionPaediatric heart transplant patients are disproportionately affected by Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disease (PTLD) compared with other childhood solid organ recipients. The drivers for this disparity remain poorly understood. A potential risk factor within this cohort is the routine surgical removal of the thymus—a gland critical for the normal development of T-lymphocyte-mediated antiviral immunity—in early life, which does not occur in other solid organ transplant recipients. Our study aims to describe the key immunological differences associated with early thymectomy, its impact on the temporal immune response to EBV infection and subsequent risk of PTLD.Methods and analysisProspective and sequential immune monitoring will be performed for 34 heart transplant recipients and 6 renal transplant patients (aged 0–18 years), stratified into early (<1 year), late (>1 year) and non-thymectomy groups. Peripheral blood samples and clinical data will be taken before transplant and at 3, 6, 12 and 24 months post-transplant. Single cell analysis of circulating immune cells and enumeration of EBV-specific T-lymphocytes will be performed using high-dimensional spectral flow cytometry with peptide-Major Histocompatibilty Complex (pMHC) I/II tetramer assay, respectively. The functional status of EBV-specific T-lymphocytes, along with EBV antibodies and viral load will be monitored at each of the predefined study time points.Ethics and disseminationEthical approval for this study has been obtained from the North of Scotland Research Ethics Committee. The results will be disseminated through publications in peer-reviewed journals, presentations at scientific conferences and patient-centred forums, including social media.Trial registration numberISRCTN10096625.